ASX Company Announcements


The edited text of our announcements are sourced from the Australian Stock Exchange and are delayed by at least 20 minutes. Retrieving the edited text of a company announcement indicates your acceptance of the Conditions.

Cellmid does not take any responsibility in respect of any of the edited text sourced from the Australian Stock Exchange

 

 27/9/2018

Appendix 4G and Corporate Governance Statement

 27/9/2018

Annual Report to Shareholders 2018

 25/9/2018

Change of Director's Interest Notice_Bruce Gordon

 24/9/2018

Clarification Announcement

 21/9/2018

CDY Investor Newsletter - 21 September 2018

 19/9/2018

Date of Annual General Meeting

 19/9/2018

Full Year Statutory Accounts

 14/9/2018

Becoming a Substantial Holder

 13/9/2018

Change of Director's Interest Notice_Cross

 13/9/2018

Change of Director's Interest Notice_Eck

 13/9/2018

Change of Director's Interest Notice_Gordon

 13/9/2018

Change of Director's Interest Notice_Halasz

 12/9/2018

Cleansing Notice

 12/9/2018

Appendix 3B

 12/09/2018

Cellmid's Lead Antibody Effective in Rare Chronic Kidney Disease

 07/09/2018

Results of the Extraordinary General Meeting of Members

 07/09/2018

EGM Presentation by CEO

 06/09/2018

 Appointment and Resignation of Company Secretary

 03/09/2018

Cellmid Share Purchase Plan Completion

 30/08/2018

Evolis USA Distribution Update

 24/08/2018

Notes to the Appendix 4E

06/08/2018

Notice of General Meeting

06/08/2018

Cleansing Notice and Appendix 3B

31/07/2018

Cellmid Share Purchase Plan

31/07/2018

Cellmid Raised $9M via Share Placement

31/07/2018

Notes to the Appendix 4C - Growing Consumer Health Sales Drive Revenue Uplift

27/07/2018

Trading Halt

11/07/2018

Cellmid Updates on Distribution of evolis

02/07/2018

 Cellmid Investor Presentation July 2018

30/05/2018

5th Midkine Symposium Reinforces Clinical Potential for Cellmid's Biotechnology Assets

29/05/2018

Change of Address

02/05/2018

Cellmid to Commence Selling evolis into Chinese Market

24/04/2018

Cellmid Secures Bloomingdales USA Partnership for evolis

23/04/2018

Appendix 4C - Quarterly

10/04/2018

Cellmid Investor Presentation

09/04/2018

Cellmid Convening 5th Midkine Symposium in Munich

04/04/2018

Cellmid Signs Distribution Agreement for Fillerina

29/03/2018 

Change of Director's Interest Notice - Halasz

26/03/2018

Initial Director's Interest Notice - Eck

26/03/2018

Cellmid Appoints Dennis Eck Non-Executive Director

14/03/2018

Change of Director's Interest Notice - Halasz

21/02/2018

Confirmation of Release - CDY - Appendix 4D and Half Year Accounts

31/01/2018

Change of Director's Interest Notice - Halasz

25/01/2018

Appendix 4C

10/01/2018

Record $2M Quarterly Sales for Cellmid's FGF5 Inhibitors

09/01/2018

Cellmid Quarterly Operational update